期刊文献+

糖尿病治疗热点靶点研究进展 被引量:13

The research advances for hot targets of diabetes treatment
原文传递
导出
摘要 糖尿病发病率高,危害大,备受关注。近来随着对其发病机制和治疗策略的研究日益深入,一些新的靶点被发现。本文综述了糖尿病治疗比较热点的靶点2013-2014年的研究进展,主要包括二肽基肽酶-4(dipeptide peptidase-4,DPP-4)、钠-葡萄糖共转运蛋白2(sodium-glucose cotransporter 2,SGLT2)、蛋白酪氨酸磷酸酶-1B(protein tyrosine phosphatase-1B,PTP-1B)、葡萄糖激酶(glucokinase,GK)、α-葡萄糖苷酶(α-glucosidase,α-Glu)和糖原合成酶激酶-3β(glycogen synthase kinase-3β,GSK-3β)等,重点突出了各个靶标的研究成果,为后续深入研究和临床应用提供参考。 Diabetes mellitus have great harm and high incidence,which attracts us a lot. With the increasing depth of the study on pathogenesis and treatment strategies of diabetes,some new targets are discovered. This article summarizes the research advances for hot targets of diabetes treatment from 2013 to 2014,mainly includes dipeptidyl peptidase-4( DPP-4),sodium-glucose cotransporter 2( SGLT2),protein tyrosine phosphatase-1B( PTP-1B),glucokinase( GK),α-glucosidase( α-Glu),glycogen synthase kinase-3β( GSK-3β) and so on,highlights the research achievements of every target,so as to provide a reference for subsequent researches and clinical applications.
出处 《中国新药杂志》 CAS CSCD 北大核心 2015年第5期526-532,共7页 Chinese Journal of New Drugs
关键词 糖尿病治疗 热点靶点 研究进展 diabetes treatment hot targets research advances
  • 相关文献

参考文献3

二级参考文献61

  • 1朱章志,熊曼琪.Ⅱ型糖尿病患者不同证型红细胞胰岛素受体缺陷的观察[J].中国中西医结合杂志,1995,15(5):266-268. 被引量:57
  • 2曾艳,贾正平,张汝学,李茂星,王娟,胡静.地黄寡糖在2型糖尿病大鼠模型上的降血糖作用及机制[J].中国药理学通报,2006,22(4):411-415. 被引量:77
  • 3易屏,陆付耳,陈广,徐丽君,王开富.小檗碱改善3T3-L1脂肪细胞胰岛素抵抗的分子机制[J].中华内分泌代谢杂志,2007,23(4):346-350. 被引量:15
  • 4American Diabetes Association. Standards of medical care in di- abetes-2012[J]. Diabetes Care, 2012, 35 (Suppl 1):S11 - S63.
  • 5DRUCKER DJ, DRITSELIS A, KIRKPATRICK P. Liraglutide [ J ]. Nat Rev Drug Discov, 2010,9 (4) :267 - 268.
  • 6ZINMAN B, SCHMIDT WE, MOSES A, et al. Achieving a clin- ically relevant composite outcome of an HbAl,. of < 7% without weight gain or hypoglyeaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme [ J ]. Diabetes Obes Metab, 2012,14( 1 ) :77 - 82.
  • 7PARKS M, ROSEBRAUGH C. Weighing risks and benefits of li- raglutide-the FDA's review of a new antidiabetie therapy [ J ]. N Engl J Med, 2010,362(9) :774 - 777.
  • 8BUSE JB, KLONOFF DC, NIELSEN LL, et al. Metabolic effeets of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an inter- im analysis of data from the open-label, uncontrolled extension of three double-blind, plaoebo-eontrolled trials [ J ]. Clin Ther, 2007, 29(1):139-153.
  • 9GALLWITZ B, GUZMAN J, DOTTA F, et al. Exenatidc twice daily versus glimepiride for prevention of glyeaemic deterioration in patients with type 2 diabetes with metformin failure (EU- REXA ) : an open-label, randomised controlled trial[ J ]. Lancet, 2012,379 ( 9833 ) : 2270 - 2278.
  • 10FONSECA VA, ALVARADO-RUIZ R, RACCAH D, et al. Effi- cacy and safety of the once-daily GLP-1 receptor agonist lixisen- atide in monotherapy: a randomized, double-blind, placebo-con- trolled trial in patients with type 2 diabetes (GetGoal-Mono) [ J]. Diabetes Care, 2012,35 (6) :1225 - 1231.

共引文献19

同被引文献172

引证文献13

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部